1-3 of 3
Alana Block
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Phase 1b Multi-Center Study of the FLT3 Inhibitor Gilteritinib in Combination with the IDH1 Inhibitor Ivosidenib or the IDH2 Inhibitor Enasidenib for Patients with Relapsed or Refractory Acute Myeloid Leukemia Who Have Co-Occurring FLT3/IDH1 or FLT3/IDH2 Mutations

Free
Eytan M. Stein, Andriy Derkach, Gabrielle Melamed, Alana Block, Janet Kim, Gergana Georgieva, Vanessa Thompson, Ross L Levine, Andrew M. Intlekofer, Omar Abdel-Wahab, Martin S. Tallman
Journal: Blood
Blood (2023) 142 (Supplement 1): 5945.
https://doi.org/10.1182/blood-2023-190801
Published: 2023
Journal Articles

Streamline - Retrospective Cohort Study of FLT3- mutated Acute Myeloid Leukemia (AML): Real-World Treatment Patterns and Clinical Outcomes after First Relapse or Refractory (R/R) Diagnosis

Free
Amer M. Zeidan, Santosh Gautam, Rebekah Yu, Ziyu Lan, David L. Grinblatt, Dina ElSouda, James Spalding, Alana Block, Maelys Touya, Bhavik J. Pandya
Journal: Blood
Blood (2022) 140 (Supplement 1): 8124–8126.
https://doi.org/10.1182/blood-2022-166692
Published: 2022
Journal Articles

Real World Outcomes in Acute Myeloid Leukemia Patients Following Post Hematopoietic Stem-Cell Transplantation Maintenance Treatment with Midostaurin or Sorafenib: A US Retrospective Cohort Study

Free
Lori Muffly, Christopher Young, Bin Xie, Alana Block, Maelys Touya, Bhavik J. Pandya
Journal: Blood
Blood (2022) 140 (Supplement 1): 8111–8112.
https://doi.org/10.1182/blood-2022-157964
Published: 2022